Clinical Trials Logo

Clinical Trial Summary

This open-label, single-arm, phase I/II clinical trial will assess the safety and efficacy of related donor adenovirus-specific T lymphocytes isolated from whole blood or leukapheresis products. The adenovirus-specific T lymphocytes will be generated automatically by the CliniMACS Prodigy using the CliniMACS Cytokine Capture System (IFN-γ) after incubation with MACS GMP PepTivator Peptide Pools of Hexon 5 for enrichment.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04722029
Study type Interventional
Source Nationwide Children's Hospital
Contact Melinda Triplet
Phone 6147226039
Email Melinda.Triplet@nationwidechildrens.org
Status Recruiting
Phase Phase 1/Phase 2
Start date October 1, 2021
Completion date October 1, 2024

See also
  Status Clinical Trial Phase
Completed NCT00711035 - Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) Phase 1/Phase 2
Completed NCT00880789 - Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus Phase 1
Terminated NCT05179057 - Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation Phase 3
Terminated NCT05305040 - Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant Phase 2/Phase 3
Completed NCT02087306 - Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection Phase 3
Active, not recruiting NCT03475212 - Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation Phase 1/Phase 2
Completed NCT00590083 - Administration of Virus-Specific Cytotoxic T-Lymphocytes Phase 1
Recruiting NCT03159364 - Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections Phase 1/Phase 2
Recruiting NCT05101213 - Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients Phase 1
Completed NCT01070797 - Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE) Phase 1
Active, not recruiting NCT04693637 - Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant Phase 2/Phase 3
Withdrawn NCT02276820 - Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A) Phase 1
Recruiting NCT02007356 - A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System® Phase 2
Withdrawn NCT02702427 - Virus-specific ImmunoTherapy Following Allogeneic Stem Cell Transplantation Phase 1/Phase 2
Completed NCT02851576 - Clinical Grade Adenovirus Specific T Cells for Immunotherapy After Allogeneic Stem Cell Transplantation (CTL-ADV) Phase 1/Phase 2
Recruiting NCT04706923 - A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection (ATHENA) Phase 2